Valuation: Geron Corporation

Market Cap 835M 728M 688M 624M 1.17B 80.14B 1.17B 8.24B 3.18B 40.75B 3.14B 3.07B 131B P/E 2026 *
-31x
P/E 2027 * 19.1x
Enterprise Value 835M 728M 688M 624M 1.17B 80.14B 1.17B 8.24B 3.18B 40.75B 3.14B 3.07B 131B EV / Sales 2026 *
3.53x
EV / Sales 2027 * 2.44x
Free-Float
99.92%
Yield 2026 *
-
Yield 2027 * -
1 day-1.52%
1 week-3.70%
Current month-12.75%
1 month-15.03%
3 months+3.17%
6 months-16.13%
Current year-1.52%
1 week 1.27
Extreme 1.27
1.4
1 month 1.27
Extreme 1.27
1.62
Current year 1.08
Extreme 1.08
2.01
1 year 1.04
Extreme 1.04
2.01
3 years 1.04
Extreme 1.04
5.34
5 years 0.99
Extreme 0.9899
5.34
10 years 0.75
Extreme 0.75
6.99
Manager TitleAgeSince
Chief Executive Officer 54 07/08/2025
Director of Finance/CFO 59 25/09/2023
Chief Tech/Sci/R&D Officer - 01/10/2025
Director TitleAgeSince
Director/Board Member 76 21/05/2010
Director/Board Member 72 28/09/2012
Director/Board Member 55 26/03/2019
Date Insider Type Main position Quantity % Market Cap. Importance
30/6/26 Free

Director

6,103 0.0010%
20/5/26 Free

Director

220,000 0.0343%
20/5/26 Free

Director

220,000 0.0343%
Change 5-day change 1-year change 3-year change Capi.($)
-1.52%-3.70%-1.52%-40.64% 848M
-0.31%+5.79%+48.93%+97.53% 70.89B
+0.39%+2.06%+40.91%+78.49% 62.32B
-3.21%-7.27%-17.73%+351.98% 27.07B
-2.64%-0.69%-0.26%-11.90% 24.78B
+0.71%+8.03%+27.22%-13.18% 20.59B
-1.26%-7.81%+169.33%+302.38% 15.52B
-0.22%+3.99%+44.28%+173.35% 14.49B
+0.73%+1.71%-7.18%+886.19% 14.14B
-0.54%-0.56%+20.59%+224.93% 12.35B
Average -0.79%+0.62%+32.46%+204.91% 26.3B
Weighted average by Cap. -0.59%+0.98%+36.17%+164.42%

Financials

2026 *2027 *
Net sales 236M 206M 195M 177M 331M 22.67B 332M 2.33B 899M 11.53B 888M 868M 37.09B 342M 298M 282M 256M 479M 32.81B 481M 3.37B 1.3B 16.68B 1.28B 1.26B 53.68B
Net income -27.18M -23.7M -22.38M -20.32M -38.08M -2.61B -38.24M -268M -103M -1.33B -102M -99.84M -4.27B 50.14M 43.73M 41.29M 37.49M 70.24M 4.81B 70.54M 495M 191M 2.45B 188M 184M 7.87B
Net Debt - -
Logo Geron Corporation
Geron Corporation is a commercial-stage biopharmaceutical company. The Company develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. It is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.
Employees
258
Date Price Change Volume
18/09/26 US$1.300 -1.52% 17,242,639
17/09/26 US$1.320 +2.33% 9,819,461
16/09/26 US$1.290 -1.53% 11,439,985
15/09/26 US$1.310 -4.38% 16,486,722
14/09/26 US$1.370 +1.48% 12,124,515
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.300USD
Average target price
4.250USD
Spread / Average Target
+226.92%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GERN Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!